Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1843 results
June 2016
-
Tackling the common denominator in liver disease
Researchers focus on reversing the scarring that’s common to liver diseases.
-
Migraine: One of the world’s most common diseases
Did you know migraine is the most common of all neurological disorders? Learn more surprising facts.
-
Media Release
Novartis erweitert Partnerschaft mit Medicines for Malaria Venture zur Entwicklung von Malariamedikamenten der nächsten Generation
Novartis wird die Entwicklung des Malariapräparats KAF156 mit wissenschaftlicher und finanzieller Unterstützung von Medicines for Malaria Venture in Zusammenarbeit mit der Bill & Melinda Gates… -
Media Release
Novartis étend son partenariat avec Medicines for Malaria Venture pour développer la prochaine génération de traitement antipaludéen
Novartis dirigera le développement de la molécule antipaludique KAF156 avec le soutien scientifique et financier de Medicines for Malaria Venture et en collaboration avec la Fondation Bill &… -
Media Release
Novartis expands partnership with Medicines for Malaria Venture to develop next-generation antimalarial treatment
Novartis will lead the development of antimalarial compound KAF156 with scientific and financial support from Medicines for Malaria Venture in collaboration with the Bill & Melinda Gates… -
Media Release
Novartis highlights long-term safety data of Revolade® in adults with chronic immune thrombocytopenia, a rare blood disorder
EXTEND study provides long-term safety data for Revolade that are consistent with the findings from the pivotal Phase III RAISE study[1,2] Immune thrombocytopenia (ITP) is a rare and potentially… -
Media Release
Novartis presents data showing Jakavi® is superior to best available therapy in patients with less advanced polycythemia vera (PV)
Three times as many patients with inadequately controlled PV without enlarged spleen had hematocrit control without phlebotomy on Jakavi® (ruxolitinib) vs BAT[1] RESPONSE-2 complements data… -
In The News
Novartis Access perspectives: Expanding access to healthcare: What will it really take?
A Medium post by Steve Davis, CEO of PATH -
Cancer researchers ready to aim for cures
New head of oncology research hopes to build on recent advances, explore new therapeutic approaches and beat certain cancers for good.
-
Confidence led this researcher to swim against the current
A researcher reflects on her successful journey from Venezuela to the US in which she became a doctor, a scientist, and a mother.
-
Media Release
New data demonstrates Sandoz' etanercept and rituximab biosimilar candidates bioequivalent to originator products
Sandoz' biosimilar etanercept candidate shows pharmacokinetic (PK) bioequivalence with no clinically meaningful differences in safety, tolerability and immunogenicity to the originator.[1] … -
Media Release
Novartis announces AMG 334 significantly reduces patients' monthly migraine days in phase II study of chronic migraine prevention
Phase II 20120295 study of AMG 334 met primary endpoint, confirming efficacy and safety in patients with chronic migraine over 12 weeks of treatment Migraine is a leading cause of disability,…
Pagination
- ‹ Previous page
- 1
- …
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- …
- 154
- › Next page
Test disclaimer...!!!